Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Opioid-Induced Swallowing Dysfunction - The Impact of Bolus Volume

11 december 2017 uppdaterad av: Johanna Savilampi, Region Örebro County

Opioid-Induced Swallowing Dysfunction - The Impact of Bolus Volume: a Randomized, Double-Blind Study in Healthy Volunteers

The purpose of the study is to evaluate the impact of different bolus volumes and viscosity on remifentanil-induced swallowing dysfunction in healthy volunteers.Hence, whether swallowing tasks can be done safer during sedation by altering bolus volumes and viscosities will be revealed. Furthermore, the study will clarify underlying mechanisms (central vs. peripheral effects) of remifentanil-induced swallowing dysfunction. If methylnaltrexone reverses the remifentanil-induced effects on swallowing, this would suggest a dominant peripherally mediated mechanism.

Studieöversikt

Detaljerad beskrivning

Monitored anesthesia care (MAC) is commonly applied in modern perioperative care and means that minor surgical procedures are accomplished in awake patients using local anesthesia and light sedation. MAC has many advantages compared to general anesthesia; the recovery time after anesthesia is shorter and risk for postoperative nausea is lower to mention some. However, the patient is spontaneously breathing and the airway is not protected by an endotracheal tube which potentially increases risk of pulmonary aspiration. Pulmonary aspiration, that is inhalation of stomach and/or pharyngeal contents into the lungs, is a severe anesthesia-related complication and can in worst case lead to pneumonia and even death. Intact swallowing function is crucial in avoiding aspiration and how sedatives and analgesic agents used during MAC influence swallowing function is not fully understood.

Pharyngeal function during bolus swallowing is measured by combined high resolution impedance manometry (HRIM). The HRIM catheter is inserted through the nose in such a way that sensors straddle the entire pharynx and esophagus with the distal catheter tip in the stomach. Dynamic pressure changes and flow can be detected during swallowing and data registered by HRIM are analysed using purpose-designed software, AIM analysis (automated impedance manometry analysis). AIM analysis derives pressure flow variables which describe different physiological events like bolus timing and bolus distension in the pharynx and the esophagus during swallowing. A Swallow Risk Index value, quantifying risk of deglutitive aspiration, can also be defined.

The aim of the study is to evaluate impact of different bolus volumes on remifentanil-induced swallowing dysfunction in healthy volunteers. The study will clarify underlying mechanisms (central vs. peripheral effects) of remifentanil-induced swallowing dysfunction. Furthermore, whether swallowing tasks can be done safer during sedation by altering bolus volumes will be revealed. In addition to bolus volume, different bolus viscosities will be tested. It is shown that higher bolus viscosity diminishes misdirected swallows in dysphagic patients and higher bolus viscosity may possibly counteracts the swallowing dysfunction induced by remifentanil. Moreover, if MNTX reverses the remifentanil-induced effects on swallowing, then this would suggest a dominant peripherally mediated mechanism. Our aim is also to evaluate impact of remifentanil exposure on esophageal motility and impact of methylnaltrexone alone on swallowing function.

20 healthy volunteers will be studied on two different occasions approximately one week apart. In a randomized order volunteers will receive intravenous infusion of remifentanil and an intravenous injection of MNTX on one occasion, and placebo (normal saline) infusion and an intravenous injection of MNTX on the other occasion. Blood samples are obtained for plasma concentration determination of the study drug and sedation levels are assessed during study drug exposure.

Studietyp

Interventionell

Inskrivning (Förväntat)

20

Fas

  • Fas 4

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år till 40 år (Vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  1. ≥ 18 - ≤ 40 year old healthy volunteers from both sexes.
  2. Have signed and dated Informed Consent.
  3. Willing and able to comply with the protocol for the duration of the trial.

Exclusion Criteria:

  1. Anamnesis of pharyngoesophageal dysfunction.
  2. Known or history of gastrointestinal, severe cardiac, pulmonary or neurological disease
  3. Ongoing medication that may affect upper gastrointestinal tract, larynx or lower airway.
  4. Allergies to or history of reaction to remifentanil, fentanyl analogues or dexmedetomidine.
  5. Pregnancy or breast feeding
  6. BMI > 30
  7. Smoking
  8. Previous participation in a medicinal clinical trial during the last year where an opioid has been used or have during the last 30 days participated in any other medicinal clinical trial or in a trial where follow-up is not completed.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Grundläggande vetenskap
  • Tilldelning: Randomiserad
  • Interventionsmodell: Crossover tilldelning
  • Maskning: Dubbel

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Aktiv komparator: RemifentanilMNTX
Volunteers are given an intravenous infusion with remifentanil, with an effect-site target concentration of 3 ng/ml via a target-controlled infusion (TCI) pump. After a series of swallowing tests an intravenous injection of methylnaltrexone of 0,3 mg/kg is given.
Remifentanil infusion TCI 3 ng/ml, Methylnaltrexone injection 0.3 mg/kg
Andra namn:
  • Ultiva
  • Relistor
  • Remifentanil
  • Metylnaltrexon
Aktiv komparator: PlaceboMNTX
Volunteers are given an intravenous infusion with saline 0,9%. After a series of swallowing tests an intravenous injection of methylnaltrexone of 0,3 mg/kg is given.
Placebo (NaCl 0.9%) TCI infusion, Methylnaltrexone injection 0.3 mg/kg
Andra namn:
  • Natriumklorid 0,9 %
  • Relistor
  • Metylnaltrexon

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Pressure Flow pharyngeal variables, 10 ml vs 20 ml bolus
Tidsram: Up to 60 minutes
Difference in pharyngeal pressure flow variables during remifentanil exposure between bolus volumes of 10 ml and 20 ml compared to placebo.
Up to 60 minutes

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Pressure Flow pharyngeal variables, liquid vs semisolid bolus
Tidsram: Up to 60 minutes
Difference in pharyngeal pressure flow variables during remifentanil exposure between liquid and semisolid boluses compared to placebo
Up to 60 minutes
Pressure Flow pharyngeal variables, remifentanil before vs after methylnaltrexone
Tidsram: Up to 60 minutes
Difference in pharyngeal pressure flow variables during remifentanil exposure before and after methylnaltrexone administration compared to placebo.
Up to 60 minutes
Pressure Flow pharyngeal variables, placebo before vs after methylnaltrexone
Tidsram: Up to 60 minutes
Difference in pharyngeal pressure flow variables during placebo infusion before and after methylnaltrexone administration.
Up to 60 minutes
Pressure Flow esophageal motility variables, 10 ml vs 20 ml bolus
Tidsram: Up to 60 minutes
Difference in variables of esophageal motility between different bolus volumes during remifentanil exposure compared to placebo.
Up to 60 minutes
Pressure Flow esophageal motility variables, liquid vs semisolid bolus
Tidsram: Up to 60 minutes
Difference in variables of esophageal motility between liquid and semisolid boluses during remifentanil exposure compared to placebo.
Up to 60 minutes
Pressure Flow esophageal motility variables, remifentanil before vs after methylnaltrexone
Tidsram: Up to 60 minutes
Difference in variables of esophageal motility during remifentanil exposure before and after methylnaltrexone administration compared to placebo.
Up to 60 minutes
Pressure Flow esophageal motility variables, placebo before vs after methylnaltrexone
Tidsram: Up to 60 minutes
Difference in variables of esophageal motility during placebo infusion before and after methylnaltrexone administration.
Up to 60 minutes

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Huvudutredare: Johanna Savilampi, MD, PhD, University Hospital in Örebro

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

11 november 2017

Primärt slutförande (Förväntat)

1 april 2018

Avslutad studie (Förväntat)

1 april 2018

Studieregistreringsdatum

Först inskickad

12 september 2017

Först inskickad som uppfyllde QC-kriterierna

12 september 2017

Första postat (Faktisk)

14 september 2017

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

12 december 2017

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

11 december 2017

Senast verifierad

1 december 2017

Mer information

Termer relaterade till denna studie

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Kliniska prövningar på Faryngeal dysfunktion

3
Prenumerera